Clin2
NCT06945523Possibly a fitRecruiting

CAR-T cell therapy for CEA-positive advanced lung cancer

Advanced Lung Cancer

Treatments studied

Part of Cancer, Lungs & breathing clinical trials.

This trial tests a treatment using your own immune cells, modified to target a protein called CEA on lung cancer cells. It's for people with advanced lung cancer that has gotten worse after at least one prior treatment.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
60 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You must be 18 or older.
  • You must have advanced lung cancer (NSCLC or SCLC) that has spread, come back, or is not responding to treatment.
  • Your cancer must have failed at least one prior therapy (like chemo, radiation, or targeted drugs).
  • Your tumor cells must test positive for a protein called CEA.
  • You must have at least one tumor that can be measured on a scan.
  • You must be in reasonably good health apart from the cancer, with adequate organ function.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06768151Recruiting· Phase 1
CEA-targeting car-t therapy for advanced lung cancer

This trial tests a new treatment called CAR-T therapy that targets a protein called CEA found on some lung cancer cells. It is for people with advanced lung cancer that has not responded to or has gotten worse after at least two standard treatments.

Wuhan, Hubei
NCT06992583Recruiting· Phase 1
CAR-T cell therapy for advanced CEA-positive lung cancer

This trial tests a new type of immune therapy called CAR-T cells that are designed to attack lung cancer cells with a specific marker called CEA. It may be an option for people with advanced lung cancer who have already tried other treatments.

Nanjing, Jiangsu
NCT06903117Recruiting· Phase 1
CAR T-Cell Therapy for CEA-Positive Advanced Lung Cancer

This early-stage trial tests a special immune cell treatment (CAR T cells) designed to target and attack lung cancer cells that have a protein called CEA on their surface. It's for people with advanced lung cancer who have already tried at least two standard treatments without success.

Shanghai
NCT07250386Recruiting· Phase 1
CEA-targeted CAR-T therapy for advanced solid tumors

This trial tests a new CAR-T cell therapy that targets CEA, a protein found on certain cancer cells. It's for people with advanced solid tumors like lung or breast cancer who have not responded to other treatments.

Hangzhou, Zhejiang
NCT06010862Recruiting· Phase 1
CAR-T therapy for CEA-positive advanced cancers

This trial tests a new type of immune cell therapy (called CAR-T) that targets a protein called CEA on cancer cells. It is for people with advanced colorectal, esophageal, stomach, or pancreatic cancer who have already tried standard treatments without success.

Nanchang, Jiangxi
NCT06006390Recruiting· Phase 1/Phase 2
CAR-T therapy for CEA-positive advanced solid tumors

This trial tests a new treatment called CAR-T cells that are designed to find and attack cancer cells carrying a protein called CEA. It is for people with advanced colorectal, esophageal, stomach, or pancreatic cancer who have already tried other treatments.

Taiyuan, Shanxi

Hear when a new Advanced Lung Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.